SMT201500174B - Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali - Google Patents

Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali

Info

Publication number
SMT201500174B
SMT201500174B SM201500174T SM201500174T SMT201500174B SM T201500174 B SMT201500174 B SM T201500174B SM 201500174 T SM201500174 T SM 201500174T SM 201500174 T SM201500174 T SM 201500174T SM T201500174 B SMT201500174 B SM T201500174B
Authority
SM
San Marino
Prior art keywords
triazolylpurins
adenosine
medicines
useful
receptor ligands
Prior art date
Application number
SM201500174T
Other languages
English (en)
Inventor
Walter Cabri
Patrizia Minetti
Giovanni Piersanti
Giorgio Tarzia
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SMT201500174B publication Critical patent/SMT201500174B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM201500174T 2009-03-20 2015-07-20 Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali SMT201500174B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09155690 2009-03-20
PCT/EP2010/053554 WO2010106145A1 (en) 2009-03-20 2010-03-18 Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments

Publications (1)

Publication Number Publication Date
SMT201500174B true SMT201500174B (it) 2015-10-30

Family

ID=40941572

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500174T SMT201500174B (it) 2009-03-20 2015-07-20 Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali

Country Status (14)

Country Link
US (2) US9133197B2 (it)
EP (1) EP2408775B1 (it)
JP (1) JP5648044B2 (it)
AR (1) AR075894A1 (it)
DK (1) DK2408775T3 (it)
ES (1) ES2542555T3 (it)
HR (1) HRP20150766T1 (it)
HU (1) HUE025704T2 (it)
PL (1) PL2408775T3 (it)
PT (1) PT2408775E (it)
SI (1) SI2408775T1 (it)
SM (1) SMT201500174B (it)
TW (1) TWI473809B (it)
WO (1) WO2010106145A1 (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
JP7433910B2 (ja) 2017-06-22 2024-02-20 ノバルティス アーゲー Cd73に対する抗体分子及びその使用
KR102254660B1 (ko) * 2017-09-28 2021-05-24 씨스톤 파마슈티컬즈 (상하이) 컴퍼니 리미티드 A2a수용체 억제제로서의 축합 고리 유도체
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
AU2019235842B2 (en) 2018-03-14 2022-02-03 Surface Oncology, Inc. Antibodies that bind CD39 and uses thereof
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112022002351A2 (pt) 2019-09-16 2022-07-19 Surface Oncology Inc Composições e métodos de anticorpo anti-cd39
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與entpd2抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンa2受容体拮抗剤
ATE242775T1 (de) 1998-01-05 2003-06-15 Eisai Co Ltd Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen
CA2376835C (en) * 1999-07-02 2009-09-15 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU3812401A (en) * 2000-02-10 2001-08-20 Univ New York Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
KR100897219B1 (ko) * 2001-06-29 2009-05-14 씨브이 쎄러퓨틱스, 인코포레이티드 A2b 아데노신 수용체 길항제로서의 퓨린 유도체
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
JPWO2003020723A1 (ja) * 2001-08-30 2004-12-16 協和醗酵工業株式会社 [1,2,4]トリアゾロ[1,5−a]ピリミジン誘導体
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法

Also Published As

Publication number Publication date
US20120053191A1 (en) 2012-03-01
PL2408775T3 (pl) 2015-10-30
EP2408775A1 (en) 2012-01-25
JP2012520854A (ja) 2012-09-10
US9133197B2 (en) 2015-09-15
WO2010106145A1 (en) 2010-09-23
TWI473809B (zh) 2015-02-21
PT2408775E (pt) 2015-08-05
EP2408775B1 (en) 2015-06-17
DK2408775T3 (en) 2015-07-27
US20160002244A1 (en) 2016-01-07
ES2542555T3 (es) 2015-08-06
HRP20150766T1 (hr) 2015-08-14
TW201100425A (en) 2011-01-01
AR075894A1 (es) 2011-05-04
SI2408775T1 (sl) 2015-08-31
JP5648044B2 (ja) 2015-01-07
HUE025704T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
SMT201500174B (it) Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CY2023012I2 (el) Παραγωγα κινολιν-8-σουλφοναμιδιου εχοντα αντικαρκινικη δραση
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201500036B (it) Derivati di cromenone con attivita' antitumorale
SMT201600099B (it) Derivati citotossici di benzodiazepine
SMT201600225B (it) DERIVATI DI 1,2,4-TIAZOLlDIN-3-0NE E LORO USO NEL TRATTAMENTO DEL CANCRO
DK2192109T3 (da) BICYKLISKE y-AMINOSYREDERIVATER
SMT201600338B (it) Formulazioni farmaceutiche comprendenti derivati di1-(beta-d- glucopiranosil)- 2-tienilmetilbenzene come inibitori di sglt
DK2511282T3 (da) Uracylspirooxetannukleosider
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
SMT201300067B (it) Applicazioni terapeutiche di derivati di chinazolindione
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
FI20085767L (fi) Kipsituote
SMT201400080B (it) Derivati di pirazinoossazepina
SMT201600262B (it) Derivati benzazolici come ligandi del recettore h4 dell'istamina
SMT201500113B (it) Processp per preparare derivati di alfa-carbossammide
SMT201400157B (it) Derivati di 2-piridin-2-il-pirazol-3(2H)-one, loropreparazione e loro uso terapeutico
SMT201500182B (it) Nuovi derivati di 8-idrossichinoline-7-carbossammidi terziarie e loro usi
FR2937549B1 (fr) Nanoparticules de derives beta-lactamine
DK2380892T3 (da) Imidazothiazolderivat med prolinringstruktur
SMT201500067B (it) Derivati di acilbenzene
FR2953410B1 (fr) Compositions antivirales pharmaceutiques ou veterinaires
BRPI1008019A2 (pt) derivados de 6-(6-substituido-triazolo piridazina-sufanil) 5-flúor-benzo-tiazóis e 5-flúor-benzimidazóis: preparo, aplicação como medicamentos e utilização como inibidores de met